Zynerba Pharmaceuticals (ZYNE)

[Cbdpotential]

Pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) announced the enrollment of the first patients into the Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy (STAR 2) clinical trial, an open-label extension trial only allowing patients who have completed the STAR 1 clinical trial to receive treatment with ZYN002 CBD gel for up to a year. "STAR 2 is designed to provide additional tolerability and safety information for ZYN002 CBD gel for up to 52 weeks, which we believe will establish that ZYN002 CBD gel is well-tolerated over long-term use," said Armando Anido, CEO of Zynerba. "Enrollment in STAR 1 is continuing and we plan to report top line results in the first half of 2017."